TickerTalks
Browse all tickers →
TickerTalks›$ISRG
ISISRG

Intuitive Surgical, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 23% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (142/wk), no spike
$ISRG·$134B·Medical - Instruments & Supplies·Healthcare
$366.70-0.8%YTD-35.0%1Y-19.3%
Mentions · last 7 days
2026-08-29: 8 posts2026-08-30: 20 posts2026-08-31: 35 posts2026-09-01: 14 posts2026-09-02: 40 posts2026-09-03: 36 posts2026-09-04: 20 posts173+34%
Price updated 5h ago·X counts updated 4h ago
ISISRG
$ISRGIntuitive Surgical, Inc.
$366.70-0.85%173 posts+34%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ISRG, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-09-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Intuitive Surgical is 37% off highs at 33x forward — a five-year valuation low on a genuine moat compounder.

Intuitive Surgical is the dominant maker of da Vinci robotic surgical systems, with a wide moat built on procedure data and hospital switching costs. The stock is down 35% YTD and 21% over the trailing year, sitting at the 16th percentile of range — a contrarian setup on a quality name.

  • The core is executing well: Q1 revenue $2.77B (+23% YoY), Q4 was +19%, 66% gross margin, 30% operating margin, and 16% ROIC — the underlying business is not the reason the stock has bled, and record cash flow gives ISRG innovation-investment room peers can't match.
  • The moat is genuinely wide: >20M surgical procedures in da Vinci AI training data, hospitals sinking $3M per platform plus team training as switching cost — a former ISRG VP publicly said 'the reliability gap rivals cannot close.' This is why the multiple compression is being called opportunity by long-term compounders.
  • Insider selling is small and routine: officer Brosius sold 77 shares each day August 17-21 (~$150K total) — a genuine 10b5-1 daily-sell pattern, not a distribution signal. No CEO or CFO conviction sales.

What breaks the coil upward is the October 20 print showing procedure-volume growth staying above 15% plus specific commentary on the next-gen SP or Ion platform pipeline. What deepens the coil is another quarter of procedure-volume deceleration, or a specific tariff/reimbursement policy change that clips the international rollout math.

Agrees with X sentimentX is bullish and the mechanics fully support it — 66% gross margin, 30% operating margin, 16% ROIC, and the da Vinci switching-cost moat are all real. The 'five-year valuation low' framing is grounded (33x forward for the moat compounder is genuinely cheap by historical standards). The rotator narrative moving from CRWD/TJX gains to ISRG is honest institutional positioning.

What to watch: October 20 Q3 earnings — procedure-volume growth above 15% and next-gen SP or Ion platform pipeline commentary. Also any tariff or reimbursement policy change affecting the international rollout math.

On the calendar: 2026-10-20 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment16 posts analyzed · as of 2026-09-04

$ISRG (Intuitive Surgical) chatter is loudly bullish. ISRG under $400 called 'a steal' at 33x forward earnings (lowest in 5 years). 20M surgical procedures in AI training data. NVDA CEO says physical AI could be 10x larger than digital AI. ISRG 38% off 52-week high ($604). T. Rowe and Invesco still holders. Da Vinci ecosystem widens moat (switching costs, training, data). 'One is a promise (TSLA), one is a business (ISRG).' Bullish.

Read the AI verdict + X sentiment for $ISRG

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes the da Vinci robotic surgery system, earning recurring revenue from instruments and service contracts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $ISRG.

Medical - Instruments & Supplies · Healthcare

Life science tools demand is tied to pharma/biotech R&D budgets; GLP-1 clinical development is a current bright spot driving CRO and instrument demand. Academic and government research funding is the more volatile demand component.

What this means for $ISRG

Partial — software subscription economics provide some insulation from macro cycles; AI integration is the growth catalyst for this segment; Intuitive Surgical, Inc.

Industry benchmark

5-name peer basket
+4.0%YTD
+12.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
50.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
16.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
30.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
14.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
17.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
66.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 16, 2026$2.80$2.48+12.9%
Q1 2026Apr 21, 2026$2.80$2.51+11.6%
Q4 2025Jan 22, 2026$2.53$2.27+11.5%
Q3 2025Oct 21, 2025$2.40$1.99+20.6%
Next earningsTue, Oct 20·consensus EPS $2.61

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.8B+23.0%66.1%30.9%$2.31$808.6M
Q4 FY25$2.9B+18.8%66.4%30.2%$2.24$730.0M
Q3 FY25$2.5B+22.9%66.4%30.3%$1.98$735.6M
Q2 FY25$2.4B+21.4%66.3%30.5%$1.84$560.1M

Forward consensus

5-year forecast · up to 26 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.8B$11.4B – $12.4B$10.80$10.49 – $10.9524
FY27$13.3B$12.8B – $13.9B$12.08$11.85 – $12.7025
FY28$15.0B$13.4B – $16.3B$13.60$11.97 – $14.9626
FY29$16.8B$16.1B – $17.8B$15.60$14.68 – $16.7425
FY30$18.5B$17.7B – $19.5B$17.00$16.00 – $18.2415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.14%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-21.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 21Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$29KSellAug 20Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$31KSellAug 19Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$30KSellAug 18Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$30KSellAug 17Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$30KSellAug 11Gary S GuthartDirector10.0K sh$4.0MSellAug 11Amy L LaddDirector72 sh$28KSellAug 10Amy L LaddDirector400 sh$152KSellAug 10Gary LoebEVP & Chief Legal and Complian400 sh$152KSellJul 31Mark BrosiusEVP & Chief Mfg and Supply Cha28 sh$10K
1–10 of 31
+ 24 other (13 exempts · 9 awards · 2 inkinds) in window

See when $ISRG insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentJul 278-K — Item 5.03: Charter amendment
AI summary

ISRG amended its articles of incorporation or bylaws. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Governance document amendments affect shareholder rights and corporate rules, and Item 5.03 requires prompt public disclosure of any such material changes.

8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change
AI summary

Intuitive Surgical, Inc. announced that Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer to Senior Vice President of Global Business Operations effective July 1, 2026. Taylor Patton, currently Global SVP Endoluminal, will succeed Charlton as the Company's new Chief Commercial and Marketing Officer. The leadership change appears to be an orderly internal transition with no indication of disagreement, and reflects the company's continued commercial expansion in surgical robotics.

8-KOfficer or director changeMay 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote · Item 7.01: Press release / Reg FD
AI summary

ISRG disclosed a personnel change (8-K Item 5.02, dated 2026-05-04). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 11 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money247wallst.com·15h ago2 Stocks Down 8% or More That Are Screaming Buys Right Nowfool.com·16h agoAre Robots the New Normal? Bet on these ETFs to Invest in the Futurezacks.com·17h agoIntuitive Surgical, Inc. $ISRG Shares Bought by AXQ Capital LPdefenseworld.net·22h ago3 Stocks Whose Competitive Walls Tower Over Nvidia'sfool.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & Humanoids

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$BAX$MDLN$NVST$WST$RGEN$LMAT$AZTA
Voices on X · top 11 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport